TORTI, DAVIDE

TORTI, DAVIDE  

SCIENZE MEDICHE  

Mostra records
Risultati 1 - 20 di 27 (tempo di esecuzione: 0.036 secondi).
Titolo Data di pubblicazione Autore(i) File
A case report of narrowing primary tracheal mucosa‑associated lymphoid tissue lymphoma: A multidisciplinary approach 2015 Maria Grazia Ruo Redda; Simona Allis; Alessia Reali; Lavinia Bianco; Silvia Maria Anglesio; Roberta Verna; Davide Torti; Guido Eugenio Parvis
A molecularly annotated platform of patient-derived xenografts (‘xenopatients’) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer 2011 Bertotti A; Migliardi G; Galimi F; Sassi F; Torti D; Isella C; Corà D; Di Nicolantonio F; Buscarino M; Petti C; Ribero D; Russolillo N; Muratore A; Massucco P; Pisacane A; Molinaro L; Valtorta E; Sartore-Bianchi A; Risio M; Capussotti L; Gambacorta M; Siena S; Medico E; Sapino A; Marsoni S; Comoglio PM; Bardelli A†; Trusolino L† (†Co-Senior authors)
A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors. 2012 D. Torti;F. Sassi;F. Galimi;S. Gastaldi;T. Perera;P. M. Comoglio;L. Trusolino*; A. Bertotti* (*Co-Senior Authors)
Diffusion-weighted quantitative MRI to diagnose benign conditions from malignancies of the anterior mediastinum: Improvement of diagnostic accuracy by comparing perfusion-free to perfusion-sensitive measurements of the apparent diffusion coefficient 2016 Priola, Adriano Massimiliano; Priola, Sandro Massimo; Gned, Dario; Piacibello, Edoardo; Sardo, Diego; Parvis, Guido; Torti, Davide; Ardissone, Francesco; Veltri, Andrea
Genetic and expression analysis of MET, MACC1 and HGF in metastatic colorectal cancer: Response to Met inhibition in patient xenografts and pathological correlations 2011 Francesco Galimi; Davide Torti; Francesco Sassi; Claudio Isella; Davide Corà; Stefania Gastaldi; Dario Ribero; Andrea Muratore; Paolo Massucco; Dimitrios Siatis; Gianluca Paraluppi; Federica Gonella; Francesca Maione; Alberto Pisacane; Ezio David; Bruno Torchio; Mauro Risio; Mauro Salizzoni; Lorenzo Capussotti; Tim Perera; Enzo Medico; M.F. Di Renzo; Paolo M. Comoglio; Livio Trusolino*; Andrea Bertotti* (*Co-Senior Authors)
Identification and pre-clinical validation of surrogate soluble biomarkers correlating with therapeutic response to met inhibition 2010 Torti D; Bertotti A; Galimi F; Gastaldi S; Sassi F; Trusolino L
INHIBITION OF MEK AND PI3K/MTOR SUPPRESSES TUMOR GROWTH BUT DOES NOT CAUSE TUMOR REGRESSION IN PATIENT-DERIVED XENOGRAFTS OF RAS-MUTANT COLORECTAL CARCINOMAS 2012 Giorgia Migliardi; Francesco Sassi; Davide Torti; Francesco Galimi; Eugenia R. Zanella; Michela Buscarino; Dario Ribero; Andrea Muratore; Paolo Massucco; Alberto Pisacane; Mauro Risio; Lorenzo Capussotti; Silvia Marsoni; Federica Di Nicolantonio; Alberto Bardelli; Paolo M. Comoglio; Livio Trusolino*; Andrea Bertotti* (*Co-Senior Authors)
Inhibition of Src impairs the growth of met-addicted gastric tumors. 2010 A. Bertotti;C. Bracco;F. Girolami;D. Torti;S. Gastaldi;F. Galimi;E. Medico;P. Elvin;P. M. Comoglio;L. Trusolino
INHIBITION OF USP7 INDUCES GROWTH ARREST AND APOPTOSIS VIA PTEN IN CLL CELLS 2015 G. Carrà, C. Panuzzo, D. Torti, G. Parvis, S. Crivellaro, A. Guerrasio, G. Saglio, A. Morotti
Inhibition OF USP7 Induces Selective Cancer Cell Death in Chronic Lymphocytic Leukemia 2016 Giovanna Carrà, Cristina Panuzzo, Davide Torti, Guido Parvis, Sabrina Crivellaro, Marco Volante, Deborah Morena, Marcello Lingua, Mara Brancaccio, Angelo Guerrasio, Pier Paolo Pandolfi, Giuseppe Saglio, Riccardo Taulli, Alessandro Morotti
INHIBITION OF USP7 INDUCES SELECTIVE CANCER CELL DEATH IN CHRONIC LYMPHOCYTIC LEUKEMIA THROUGH PTEN AND INDEPENDENTLY FROM P53 STATUS 2016 G Carrà, C Panuzzo, S Crivellaro, D Torti, G Parvis, U Familiari, M Volante, D Morena, MF Lingua, M Brancaccio, A Guerrasio, PP Pandolfi, G Saglio, R Taulli, A Morotti
Met as a potential therapeutic target in basal-like breast cancer 2010 Gastaldi S; Bertotti A; Galimi F; Sassi F; Torti D; Smalley M; Trusolino L
Met as a potential therapeutic target in basal-like breast cancer: An in vivo approach in a stem-cell perspective 2009 Gastaldi S; Bertotti A; Bracco C; Galimi F; Torti D; Trusolino L
Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer. 2013 S. Gastaldi; F. Sassi; P. Accornero; D. Torti; F. Galimi; G. Migliardi; G. Molyneux; T. Perera; P. M. Comoglio; C. Boccaccio; M. J. Smalley; A. Bertotti*; L. Trusolino* (*Co-Senior Authors)
MET SIGNALING REGULATES GROWTH, REPOPULATING POTENTIAL AND BASAL CELL-FATE COMMITMENT OF MAMMARY LUMINAL PROGENITORS: IMPLICATIONS FOR BASAL-LIKE BREAST CANCER. 2012 Paolo Accornero; Stefania Gastaldi; Francesco Sassi; Davide Torti; Silvia Miretti; Eugenio Martignani; Mario Baratta; Matthew J Smalley; Andrea Bertotti; Livio Trusolino
NEW ALTERNATIVE PROTEIN Bcr/Abl-OOF SHOWS ONCOGENIC ACTIVITY BY ACTIVATION OF RAC AND COOPERATION WITH Bcr/Abl IN CHRONIC MYELOID LEUKEMIA. 2015 C. Panuzzo, G. Volpe, E. Cibrario Rocchietti, C. Casnici, K. Crotta, S. Crivellaro, G. Carrà, F. Daraio, R. Lorenzatti, D. Torti, A. Morotti,O. Marelli, G. Saglio
New alternative splicing BCR/ABL-OOF shows an oncogenic role by lack of inhibition of BCR GTPase activity and an increased of persistence of Rac activation in chronic myeloid leukemia 2015 Panuzzo, Cristina; Volpe, Gisella; Cibrario Rocchietti, Elisa; Casnici, Claudia; Crotta, Katia; Crivellaro, Sabrina; Carrà, Giovanna; Lorenzatti, Roberta; Peracino, Barbara; Torti, Davide; Morotti, Alessandro; Camacho-Leal, Maria Pilar; Defilippi, Paola; Marelli, Ornella; Saglio, Giuseppe
Non genomic loss of function of tumor suppressors in CML: BCR-ABL promotes IκBα mediated p53 nuclear exclusion 2015 Crivellaro, Sabrina; Panuzzo, Cristina; Carrà, Giovanna; Volpengo, Alessandro; Crasto, Francesca; Gottardi, Enrico; Familiari, Ubaldo; Papotti, Mauro; Torti, Davide; Piazza, Rocco; Redaelli, Sara; Taulli, Riccardo; Guerrasio, Angelo; Saglio, Giuseppe; Morotti, Alessandro
Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils 2011 Torti D; Trusolino L
Only a subset of Met-activated pathways are required to sustain oncogene addiction 2009 Bertotti A; Burbridge MF; Gastaldi S; Galimi F; Torti D; Medico E; Giordano S; Corso S; Rolland-Valognes G; Lockhart BP; Hickman JA; Comoglio PM; Trusolino L.